FindTrial
Sign In

RP2

BIOLOGICAL7 trials

Sponsors

Replimune Inc., Replimune Group Inc., Abramson Cancer Center at Penn Medicine

Conditions

Advanced solid tumorsBiliary Tract CancerCancerEsophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaMSS

Phase 1

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Active, not recruitingNCT04336241
Replimune Inc.Cancer
Start: 2019-10-17End: 2026-10-31Target: 36Updated: 2026-02-27

Phase 2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RecruitingNCT05733598
Replimune Inc.Biliary Tract Cancer, Hepatocellular Carcinoma
Start: 2024-08-01End: 2028-07-01Target: 60Updated: 2026-04-02
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
TerminatedNCT05733611
Replimune Inc.MSS, pMMR, Refractory Metastatic Colorectal Cancer
Start: 2023-06-29End: 2025-08-18Updated: 2026-02-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingNCT06581406
Replimune Inc.Metastatic Uveal Melanoma
Start: 2024-12-17End: 2031-10-01Target: 280Updated: 2026-04-02
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
Not yet recruitingNCT07059611
Abramson Cancer Center at Penn MedicineEsophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Start: 2026-04-01End: 2029-11-01Target: 34Updated: 2026-01-12
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
Not yet recruitingCTIS2023-508784-68-00
Replimune Inc.metastatic uveal melanoma
Target: 98Updated: 2026-01-12

Phase 4

Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
Not yet recruitingCTIS2025-521621-33-00
Replimune Group Inc.Advanced solid tumors, Hepatocellular Carcinoma, Melanoma +1
Target: 13Updated: 2026-02-09

Related Papers

A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC).
Journal of Clinical Oncology2026-01-10
A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
Journal of Clinical Oncology2025-05-281 citations
A multicenter, open-label study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2025-01-27
Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.
Journal of Clinical Oncology2024-06-019 citations
An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
Journal of Clinical Oncology2024-06-013 citations
Abstract 2467: Enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumab
Cancer Research2024-03-221 citations
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Journal of Clinical Oncology2024-01-202 citations
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
Journal of Clinical Oncology2024-01-201 citations
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
Journal of Clinical Oncology2023-06-017 citations
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Journal of Clinical Oncology2023-06-011 citations
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
Journal of Clinical Oncology2023-06-01
575 Safety and feasibility of intratumoral injection of the RPx family of oncolytic immunotherapies in patients with liver metastasis
Regular and Young Investigator Award Abstracts2022-11-01
Abstract CT155: Clinical biomarker studies with an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors indicates potent immune activation
Cancer Research2022-06-15
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-013 citations
507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts2021-11-011 citations
Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation
Cancer Research2021-07-013 citations
421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
Regular and Young Investigator Award Abstracts2020-11-017 citations